Skip to main content

Table 1 Baseline characteristics of trials included in the meta-analysis

From: Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis

Author (Publication Date) Trial phase Tumor staging Interventions Age (media, years) follow-up (media,wk) No. of EP Jadad score
Coombes(2007) Phase 3 trial Early-stage breast cancer Exemestane (25 mg/d)   55.7 months 2320 5
Velde(2011) Phase 3 trial Early-stage breast cancer Exemestane (25 mg/d) 64 (35–96) 61.2 months 9666 5
Exemestane (25 mg/d)
Arimidex(2008) Phase 3 trial Early-stage breast cancer Anastrozole (1 mg/d) 64 (9) mean sd 100 months 3092 4
Hiroji(2013) Phase 3 trial Advanced-stage breast cancer Exemestane (25 mg/d) 64 (9) mean sd 60.1 months (48.2, NR) 298 3
Anastrozole (1 mg/d)
Buzdar(1998) Phase 3 trial Advanced-stage breast cancer Anastrozole (1 mg/d) 65.6 ± 10.9 31 months 508 3
Anastrozole (10 mg/d) 66 ± 10.4
Boccardo(2005) Phase 3 trial Early-stage breast cancer Anastrozole (1 mg/d) 63 (38–76) 36 months 223 4
Coates(2007) Phase 3 trial Early-stage breast cancer Letrozole(2.5 mg/d)   51 months 2448 5
Kaufmann(2007) Phase 3 trial Early-stage breast cancer Anastrozole (1 mg/d) 60.9 mean 30.1 months 445 5
Coombes(2004) Phase 3 trial Early-stage breast cancer Exemestane (25 mg/d) 64.3 ± 8.1 mean SD 30.6 months 2362 4
Paul(2013) Phase 3 trial Early-stage breast cancer Exemestane (25 mg/d) 63.9 49.2 months 7576 3
Anastrozole (1 mg/d) 64.3
Baum(2003) Phase 3 trial Early-stage breast cancer Anastrozole (1 mg/d)   33 months 3902 4
Joyce(2017) Phase 3 trial Advanced-stage breast cancer Ribociclib + Letrozole(2.5 mg/d) 62.5 (37.0–82.0)   226 3
Letrozole(2.5 mg/d) 63.0 (29.0–88.0)  
Colleoni(2017) Phase 3 trial Early-stage breast cancer Continuous Letrozole(2.5 mg/d) 60 (54–67) 60 months 4828 5
Intermittent Letrozole(2.5 mg/d)
Tamar(2017) Phase 2 trial Advanced-stage breast cancer Everolimus(10 mg/d) plus Letrozole(2.5 mg/d) 62.5 (34.6–82.0) 11.4 months 72 3
Gabe(2017) Phase 3 trial Advanced-stage breast cancer Ribociclib(600 mg/d) plus Letrozole(2.5 mg/d)    674 3
Letrozole(2.5 mg/d)    
Vivianne(2017) Phase 3 trial Early-stage breast cancer Anastrozole (1 mg/d) 57.6 (51.2–64.5) 50.4 months 1660 5
Anastrozole (1 mg/d) 57.7 (51.9–64.3)
Smith(2017) Phase 3 trial Early-stage breast cancer Letrozole(2.5 mg/d) 62 (33–96) 65 months 4111 5
Anastrozole (1 mg/d) 62 (33–92)
  1. date as show with number (percentage);
  2. No. of EP Number of enrolled patients; NR not reported